Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Held by: VTI IWM VXF IWN IBB FESM SCHA DWAS VTWO VFMO

Index	RUT	P/E	-	EPS (ttm)	-2.11	Insider Own	31.43%	Shs Outstand	35.85M	Perf Week	-3.67%
Market Cap	824.89M	Forward P/E	-	EPS next Y	-2.85	Insider Trans	-2.68%	Shs Float	28.63M	Perf Month	-8.15%
Enterprise Value	546.24M	PEG	-	EPS next Q	-0.76	Inst Own	32.36%	Short Float	3.18%	Perf Quarter	155.91%
Income	-75.79M	P/S	139.34	EPS this Y	65.51%	Inst Trans	1.75%	Short Ratio	1.41	Perf Half Y	334.21%
Sales	5.92M	P/B	2.55	EPS next Y	-24.47%	ROA	-23.59%	Short Interest	0.91M	Perf YTD	49.33%
Book/sh	7.74	P/C	2.89	EPS next 5Y	25.86%	ROE	-25.64%	52W High	24.00 -17.68%	Perf Year	312.45%
Cash/sh	6.84	P/FCF	-	EPS past 3/5Y	-30.62% -	ROIC	-27.08%	52W Low	2.88 585.99%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	96.77%	Volatility	7.24% 7.48%	Perf 5Y	-
Dividend TTM	-	EV/Sales	92.27	EPS Y/Y TTM	-1.89%	Oper. Margin	-1516.29%	ATR (14)	1.43	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	11.87	Sales Y/Y TTM	-	Profit Margin	-1280.90%	RSI (14)	56.91	Recom	2.20
Dividend Gr. 3/5Y	- -	Current Ratio	11.87	EPS Q/Q	17.81%	SMA20	-0.08%	Beta	1.41	Target Price	30.00
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	19.72%	Rel Volume	0.48	Prev Close	19.57
Employees	64	LT Debt/Eq	0.01	Earnings	Nov 06 AMC	SMA200	143.90%	Avg Volume	644.58K	Price	19.76
IPO	Sep 26, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.04% 164.18%	Trades		Volume	236,426	Change	0.95%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-26	Initiated	Piper Sandler	Overweight	$73
Dec-05-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$12
Oct-22-25	Upgrade	Citigroup	Neutral → Buy	$10
Feb-28-25	Initiated	William Blair	Mkt Perform
Dec-10-24	Downgrade	Morgan Stanley	Overweight → Underweight	$40 → $5
Dec-09-24	Downgrade	Jefferies	Buy → Hold	$42 → $7
Dec-09-24	Downgrade	Citigroup	Buy → Neutral	$45 → $7
Oct-21-24	Initiated	Morgan Stanley	Overweight	$40
Oct-21-24	Initiated	Jefferies	Buy	$42
Oct-21-24	Initiated	Citigroup	Buy	$45

Jan-29-26 03:00AM	Eli Lilly, BioAge chase NLRP3 inhibitors with pipeline in a pill potential (Pharma Voice)
Jan-21-26 10:30PM	BioAge Announces Pricing of Upsized $115.0 Million Public Offering (GlobeNewswire) -5.63% -6.06%
Jan-20-26 04:01PM	BioAge Announces Proposed Public Offering (GlobeNewswire) +5.75%
09:00AM	BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 (GlobeNewswire)
Jan-12-26 01:06PM	BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio (Investor's Business Daily) +27.23%
09:00AM	Loading…
09:00AM	BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk (GlobeNewswire)
Dec-13-25 10:35AM	2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole (Motley Fool)
Dec-04-25 09:00AM	BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (GlobeNewswire) +13.88%
Nov-25-25 04:30PM	BioAge Labs to Present at Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-07-25 09:00AM	BioAge Labs to Present at Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-06-25 04:45PM	BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-05-25 07:45AM	Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy (Motley Fool)
Oct-29-25 06:15AM	Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026? (Motley Fool)
Oct-26-25 06:33PM	BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher? (Motley Fool)
Oct-23-25 07:36AM	Ventyx shares soar after study suggests cardiovascular benefits for experimental drug (BioPharma Dive) +31.40%
04:30PM	Loading…
Aug-20-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 07:36AM	BioAge commences dosing in trial of obesity treatment candidate BGE-102 (Clinical Trials Arena)
Aug-15-25 09:00AM	BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor (GlobeNewswire)
Aug-06-25 04:30PM	BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-29-25 10:23AM	BioAge (BIOA) to Analyze Over 17,000 Biobank Samples for Drug Discovery (Insider Monkey)
Jun-21-25 06:00PM	BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions (GlobeNewswire)
Jun-17-25 09:00AM	BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank (GlobeNewswire)
Jun-03-25 09:00AM	BioAge Expands APJ Agonist Pipeline with Oral Small-Molecule and Long-Acting Biologic Candidates (GlobeNewswire)
May-30-25 09:05AM	BioAge Labs completes IND-enabling studies for BGE-102 (TipRanks)
May-29-25 11:18PM	BioAge Labs, Inc. (BIOA)'s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025 (Insider Monkey)
09:00AM	BioAge Labs completes IND-enabling studies for BGE-102, a potent, orally available, brain-penetrant NLRP3 inhibitor, and advances candidate toward the clinic (GlobeNewswire)
May-27-25 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
May-06-25 04:30PM	BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-21-25 01:02PM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Mar-22-25 11:00AM	Investors To Focus On PCE Price Index Print As Cintas, Lululemon To Report Earnings (SeekingAlpha)
04:30PM	Loading…
Mar-20-25 04:30PM	BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024 (GlobeNewswire)
Mar-17-25 01:54PM	BioArctic receives Orphan Drug Designation for exidavnemab the US (PR Newswire)
Mar-04-25 05:07AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-20-25 04:30PM	BioAge Labs to Participate in TD Cowen's 45th Annual Health Care Conference (GlobeNewswire)
10:36AM	BioAge Labs (BIOA) Abandons Obesity Drug Amid Shareholder Lawsuit - Hagens Berman (Newsfile)
Feb-16-25 07:18AM	BIOA COURT NEWS: BioAge Labs has been Sued for Securities Violations; Contact BFA Law by March 10 if You Lost Money (NASDAQ:BIOA) (GlobeNewswire)
Feb-14-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire) +5.97%
Feb-13-25 08:42AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Feb-07-25 05:45AM	BioAge Labs, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-30-25 09:01AM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (Newsfile)
Jan-29-25 05:39AM	BioAge drops obesity drug; Akero, 89bio cash in on MASH data (BioPharma Dive) -6.40%
Jan-28-25 07:27PM	Kessler Topaz Meltzer & Check, LLP Encourages BioAge Labs, Inc. Investors with Losses to Contact the Firm (PR Newswire)
09:00AM	BioAge Labs Announces Company Updates on APJ, NLRP3, and Platform Programs (GlobeNewswire)
Jan-24-25 05:45AM	Shareholders of BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-22-25 03:00AM	After an obesity stumble, BioAge reconnects with its longevity pipeline (Pharma Voice)
Jan-21-25 05:45AM	Investors in BioAge Labs, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights - BIOA (PR Newswire)
Jan-18-25 03:07AM	BIOAGE LABS (BIOA) Investors are Notified the Company has been Sued and are Urged to Contact BFA Law by March 10 (Newsfile)
Jan-06-25 09:00PM	Bragar Eagel and Squire, P.C. Is Investigating Franklin, MediaAlpha, e.l.f. Beauty, and BioAge and Encourages Investors to Contact the Firm (GlobeNewswire) -7.39%
Jan-03-25 12:51PM	BioAge Labs (BIOA) Shares Plummet After Discontinuing Trial Just 2 Months After IPO- Hagens Berman (PR Newswire)
Jan-02-25 09:35AM	BioAge Labs, Inc. (BIOA) Loses -67.99% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-01-25 05:00AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-27-24 11:32AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -6.46%
09:18AM	BioAge Labs, Inc. (BIOA): A Bull Case Theory (Insider Monkey)
Dec-26-24 07:23AM	Kirby McInerney LLP is Investigating Potential Shareholder Claims Against BioAge Labs, Inc. (BIOA) (Newsfile)
Dec-25-24 07:04AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile)
Dec-23-24 10:19AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-19-24 01:15PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) +20.23%
05:46AM	BioAge and Novartis seek drug targets for ageing-related diseases (Pharmaceutical Technology)
Dec-18-24 09:00AM	BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions (GlobeNewswire)
Dec-16-24 04:20PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
03:00AM	3 closely watched drugs that failed in the clinic (Pharma Voice)
Dec-13-24 10:31AM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman (Newsfile) -6.75%
Dec-12-24 06:34PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire)
Dec-09-24 07:51PM	BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures Hagens Berman (GlobeNewswire) -76.85%
09:28AM	BioAge halts ongoing Phase II trial of obesity drug due to liver concerns (Clinical Trials Arena)
07:41AM	Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns (Benzinga)
Dec-07-24 06:34AM	BioAge shares tumble after decision to halt obesity drug study (BioPharma Dive)
Dec-06-24 04:35PM	BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity (GlobeNewswire) +9.36% -76.85%
Dec-05-24 04:30PM	BioAge Labs to Present at Goldman Sachs Year-Ahead Catalyst Clinic (GlobeNewswire)
Dec-04-24 04:47PM	Why BioAge Labs (BIOA) is the Best All-Time Low Stock to Buy Right Now? (Insider Monkey)
Nov-21-24 04:30PM	BioAge Labs to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 11:01PM	BioAge Labs Reports Strong Q3 2024 Achievements (TipRanks) -11.78%
Nov-07-24 04:30PM	BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -10.11% +7.61%
Nov-04-24 09:00AM	BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 (GlobeNewswire)
Oct-24-24 09:00AM	BioAge Labs to Present at Jefferies London Healthcare Conference (GlobeNewswire)
Oct-21-24 10:53AM	Wall Street analysts initiate coverage of BioAge Labs (Investing.com) +8.26%
Oct-17-24 09:45AM	Prediction: These 2 Stocks Could Soar in 2025 (Motley Fool)
Oct-12-24 02:31PM	Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock (Motley Fool)
Oct-07-24 09:10PM	RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc (GuruFocus.com)
Oct-05-24 07:15AM	3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October (Motley Fool)
Oct-03-24 09:05AM	This IPO Biotech Stock Could Be the Next Eli Lilly (Motley Fool) +5.73%
Oct-01-24 04:30PM	BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters' Option to Purchase Additional Shares and Closing of the Concurrent Private Placement (GlobeNewswire)
Sep-26-24 04:08PM	BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO (Investor's Business Daily)
02:36PM	A weight loss drug developer's stock soars after a $198 million IPO (Quartz)
08:25AM	BioAge Labs IPO: Stock price will be closely watched today as the obesity drug developer debuts on the Nasdaq (FastCompany)
Sep-25-24 08:00PM	BioAge Labs Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
04:13PM	BioAge prices $198M IPO, validating pivot to obesity drug research (BioPharma Dive)
11:27AM	A weight loss drug maker is aiming for a big IPO (Quartz)

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapeutic products for metabolic diseases, such as obesity, by targeting the biology of human beings. It offers Azelaprag, a potential oral therapeutic for obesity, followed by several earlier-stage metabolic programs. The company was founded by Kristen Fortney and Eric Morgen on April 1, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RUBIN PAUL D	Chief Medical Officer	Feb 02 '26	Option Exercise	4.77	7,433	35,470	7,433	Feb 03 04:26 PM
RUBIN PAUL D	Chief Medical Officer	Feb 02 '26	Sale	18.75	7,433	139,369	0	Feb 03 04:26 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Feb 01 '26	Option Exercise	4.38	3,541	15,510	29,491	Feb 03 04:23 PM
RUBIN PAUL D	Officer	Feb 02 '26	Proposed Sale	18.75	7,433	139,369		Feb 02 09:43 AM
GOLDSTEIN DOV A MD	Chief Financial Officer	Jan 16 '26	Option Exercise	4.38	3,542	15,514	25,950	Jan 21 04:20 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Jan 13 '26	Option Exercise	8.39	27,000	226,530	49,408	Jan 15 04:22 PM
GOLDSTEIN DOV A MD	Chief Financial Officer	Jan 13 '26	Sale	19.70	27,000	531,828	22,408	Jan 15 04:22 PM
Fortney Kristen	Chief Executive Officer	Jan 13 '26	Sale	18.12	233,107	4,223,036	976,949	Jan 15 04:20 PM
Fortney Kristen	10% Owner	Jan 13 '26	Proposed Sale	18.00	233,107	4,195,926		Jan 13 04:36 PM
GOLDSTEIN DOV A MD	Officer	Jan 13 '26	Proposed Sale	19.70	27,000	531,828		Jan 13 04:16 PM
RUBIN PAUL D	Chief Medical Officer	Jan 02 '26	Option Exercise	4.77	7,433	35,470	7,433	Jan 06 04:24 PM
RUBIN PAUL D	Chief Medical Officer	Jan 02 '26	Sale	12.85	7,433	95,490	0	Jan 06 04:24 PM
RUBIN PAUL D	Officer	Jan 02 '26	Proposed Sale	13.41	7,433	99,677		Jan 02 12:56 PM
RUBIN PAUL D	Chief Medical Officer	Dec 09 '25	Option Exercise	6.57	18,000	118,260	18,000	Dec 11 04:21 PM
RUBIN PAUL D	Chief Medical Officer	Dec 09 '25	Sale	12.00	18,000	216,000	0	Dec 11 04:21 PM
RUBIN PAUL D	Officer	Dec 09 '25	Proposed Sale	12.00	18,000	216,000		Dec 09 11:23 AM
RUBIN PAUL D	Chief Medical Officer	Dec 04 '25	Option Exercise	4.11	68,897	283,167	68,897	Dec 05 06:20 PM
RUBIN PAUL D	Chief Medical Officer	Dec 04 '25	Sale	10.19	68,897	701,909	0	Dec 05 06:20 PM
RUBIN PAUL D	Officer	Dec 04 '25	Proposed Sale	10.19	68,897	701,912		Dec 04 04:30 PM

Open in Screener

ZBIO

Zenas Biopharma Inc

Feb 17 • 02:24PM ET

27.13

+0.73 2.77 %

Healthcare • Biotechnology • USA • NASD

ZBIO Zenas Biopharma Inc daily Stock Chart

Held by: VTI IWM VXF IBB IWN SCHA VFMO FFSM DWAS VTWO

Index	RUT	P/E	-	EPS (ttm)	-4.53	Insider Own	59.43%	Shs Outstand	42.21M	Perf Week	20.69%
Market Cap	1.46B	Forward P/E	-	EPS next Y	-4.50	Insider Trans	3.86%	Shs Float	21.78M	Perf Month	36.13%
Enterprise Value	1.17B	PEG	-	EPS next Q	-1.00	Inst Own	35.50%	Short Float	30.16%	Perf Quarter	-23.92%
Income	-189.90M	P/S	97.09	EPS this Y	65.34%	Inst Trans	9.31%	Short Ratio	8.69	Perf Half Y	61.30%
Sales	15.00M	P/B	5.83	EPS next Y	-9.13%	ROA	-52.35%	Short Interest	6.57M	Perf YTD	-25.28%
Book/sh	4.65	P/C	5.01	EPS next 5Y	31.84%	ROE	-68.33%	52W High	44.60 -39.17%	Perf Year	289.24%
Cash/sh	5.42	P/FCF	-	EPS past 3/5Y	-9.85% -	ROIC	-96.59%	52W Low	6.11 344.03%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	99.47%	Volatility	10.38% 9.52%	Perf 5Y	-
Dividend TTM	-	EV/Sales	77.75	EPS Y/Y TTM	-38.04%	Oper. Margin	-1304.64%	ATR (14)	2.48	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.66	Sales Y/Y TTM	-70.00%	Profit Margin	-1265.99%	RSI (14)	60.46	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	5.66	EPS Q/Q	-32.20%	SMA20	26.40%	Beta	-2.02	Target Price	40.75
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-1.90%	Rel Volume	0.86	Prev Close	26.40
Employees	130	LT Debt/Eq	0.00	Earnings	Nov 12 BMO	SMA200	28.76%	Avg Volume	755.95K	Price	27.13
IPO	Sep 13, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.57% -100.00%	Trades		Volume	496,058	Change	2.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-05-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Mar-20-25	Initiated	Wedbush	Outperform	$35
Feb-04-25	Initiated	Wolfe Research	Outperform	$19
Dec-16-24	Initiated	H.C. Wainwright	Buy	$30
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$34
Oct-08-24	Initiated	Morgan Stanley	Overweight	$40
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$45
Oct-08-24	Initiated	Citigroup	Buy	$27

Feb-16-26 04:07AM	Zenas BioPharma Highlights Obexelimab Phase 3 Win, Targets Q2 BLA Filing at Guggenheim Summit (MarketBeat)
Feb-09-26 07:05AM	Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 (GlobeNewswire)
Feb-04-26 07:05AM	Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-16-26 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-10-26 09:01AM	Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Benzinga)
06:46AM	Loading…
Jan-07-26 06:46AM	Zenas BioPharma Touts Phase 3 Win, But Stock Crashes (Benzinga) +8.62%
Jan-06-26 11:18AM	ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study (Zacks) -8.49%
06:25AM	Zenas stock drops 51% despite lead assets Phase III rare disease win (Clinical Trials Arena)
Jan-05-26 04:23PM	Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed. (Investor's Business Daily) -51.86%
07:05AM	Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
06:26AM	Zenas shares crash after top drug misses expectations in immune disease study (BioPharma Dive)
Dec-19-25 04:15PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +17.10%
Dec-15-25 07:05AM	Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus (GlobeNewswire) -19.71%
Dec-12-25 09:45AM	Huge Insider Buying in MGM and Salesforce (24/7 Wall St.)
Dec-03-25 07:25AM	Meridian Small Cap Growth Fund Trimmed Zenas BioPharma (ZBIO) Following Share Price Appreciation (Insider Monkey) +6.29%
07:05AM	Loading…
Nov-12-25 07:05AM	Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-11-25 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire) +8.41%
Oct-31-25 12:41PM	How Royalty Pharma Prints Cash Without Biotech's Biggest Risks (MarketBeat)
Oct-28-25 01:34PM	1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data (MarketBeat) -5.06%
08:35AM	Zenas bifunctional mAb scores at Phase II in relapsing MS (Clinical Trials Arena)
06:00AM	Incyte trims pipeline; Zenas surges on MS drug results (BioPharma Dive)
Oct-27-25 07:05AM	Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis (GlobeNewswire) +33.08%
Oct-08-25 05:00AM	Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis (GlobeNewswire) +24.22%
Sep-02-25 07:05AM	Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million (GlobeNewswire) +9.50%
Aug-26-25 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-12-25 07:05AM	Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +6.68%
Jun-20-25 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-13-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -8.75%
Jun-02-25 04:00AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) +5.67%
May-29-25 07:05AM	Zenas BioPharma to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.34%
09:31AM	Loading…
May-28-25 09:31AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) -12.59%
May-16-25 05:45AM	Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +7.49%
May-15-25 07:05AM	Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +12.21%
May-06-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -19.71%
May-02-25 05:45AM	Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire)
Apr-29-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +12.56%
Apr-22-25 10:37AM	Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses (GlobeNewswire)
Apr-21-25 12:33PM	Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses (GlobeNewswire) +9.30%
Apr-17-25 04:20PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.08%
Apr-07-25 03:08PM	Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst (Seeking Alpha)
07:05AM	Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-20-25 02:54PM	Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress (Benzinga)
11:41AM	Zenas Bio rises as Wedbush launches with Outperform on lead asset (SeekingAlpha)
Mar-17-25 07:05AM	Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer (GlobeNewswire)
Feb-05-25 07:05AM	Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases (GlobeNewswire)
Jan-28-25 08:00AM	Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-17-24 06:25AM	Zenas BioPharma initiated with a Buy at H.C. Wainwright (TipRanks) +8.10%
Dec-12-24 07:35AM	Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley (TipRanks)
Nov-12-24 07:10AM	Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:05AM	Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
Nov-07-24 07:05AM	Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +7.63%
Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +8.45%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lu Hongbo	Director	Feb 11 '26	Buy	22.50	25,985	584,662	347,968	Feb 13 05:35 PM
Allen Patricia L	Director	Feb 12 '26	Buy	24.85	15,700	390,088	15,700	Feb 13 05:06 PM
Allen Patricia L	Director	Feb 13 '26	Buy	26.36	4,160	109,658	19,860	Feb 13 05:06 PM
MOULDER LEON O JR	Chief Executive Officer	Feb 02 '26	Buy	17.96	57,000	1,023,720	423,155	Feb 03 04:30 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 07 '26	Buy	16.38	50,000	819,000	316,155	Jan 09 09:42 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 08 '26	Buy	16.30	30,000	489,000	346,155	Jan 09 09:42 PM
MOULDER LEON O JR	Chief Executive Officer	Jan 09 '26	Buy	16.55	20,000	331,000	366,155	Jan 09 09:42 PM
Nunn Jason Raleigh	Director	Oct 09 '25	Buy	19.00	63,158	1,200,002	1,173,395	Oct 14 05:16 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Oct 09 '25	Buy	19.00	126,315	2,399,985	1,917,895	Oct 14 05:14 PM
ENRIGHT PATRICK G	Director	Oct 09 '25	Buy	19.00	105,265	2,000,035	1,832,669	Oct 14 08:59 AM
ENRIGHT PATRICK G	Director	Oct 09 '25	Buy	20.85	11,990	249,992	11,990	Oct 14 08:59 AM
MOULDER LEON O JR	See Remarks	Oct 07 '25	Buy	20.85	36,928	769,949	36,928	Oct 09 05:24 PM
Fairmount Funds Management LLC	Director	Oct 07 '25	Buy	19.00	316,219	6,008,161	2,209,025	Oct 09 04:15 PM
Lu Hongbo	Director	Oct 07 '25	Buy	19.00	263,160	5,000,040	321,983	Oct 09 03:37 PM
MOULDER LEON O JR	Chief Executive Officer	Feb 18 '25	Buy	6.67	25,000	166,750	266,155	Feb 19 04:01 PM

Open in Screener

JAZZ

Jazz Pharmaceuticals plc

Feb 17 • 02:24PM ET

167.79

+1.48 0.89 %

Healthcare • Biotechnology • Ireland • NASD

JAZZ Jazz Pharmaceuticals plc daily Stock Chart

Peers: VRTX REGN BIIB INCY GILD BMRN NBIX EXEL UTHR SAGE

| Held by: IJH VTI VB VBR VXF MDY IJK COWG SPMD CALF

Index	-	P/E	-	EPS (ttm)	-6.07	Insider Own	4.67%	Shs Outstand	60.74M	Perf Week	1.69%
Market Cap	10.20B	Forward P/E	7.61	EPS next Y	22.04	Insider Trans	-4.55%	Shs Float	57.93M	Perf Month	-1.97%
Enterprise Value	13.58B	PEG	1.16	EPS next Q	6.52	Inst Own	100.38%	Short Float	9.78%	Perf Quarter	18.40%
Income	-368.48M	P/S	2.45	EPS this Y	-60.80%	Inst Trans	1.49%	Short Ratio	4.82	Perf Half Y	42.47%
Sales	4.16B	P/B	2.57	EPS next Y	169.06%	ROA	-3.12%	Short Interest	5.66M	Perf YTD	-1.30%
Book/sh	65.18	P/C	4.98	EPS next 5Y	6.58%	ROE	-9.06%	52W High	182.99 -8.31%	Perf Year	25.25%
Cash/sh	33.67	P/FCF	7.63	EPS past 3/5Y	- -1.00%	ROIC	-4.42%	52W Low	95.49 75.71%	Perf 3Y	13.58%
Dividend Est.	-	EV/EBITDA	11.31	Sales past 3/5Y	9.56% 13.48%	Gross Margin	73.01%	Volatility	2.36% 2.51%	Perf 5Y	2.14%
Dividend TTM	-	EV/Sales	3.27	EPS Y/Y TTM	-179.96%	Oper. Margin	12.39%	ATR (14)	4.31	Perf 10Y	36.65%
Dividend Ex-Date	-	Quick Ratio	1.44	Sales Y/Y TTM	4.14%	Profit Margin	-8.86%	RSI (14)	53.42	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	1.65	EPS Q/Q	19.88%	SMA20	0.76%	Beta	0.25	Target Price	221.07
Payout	0.00%	Debt/Eq	1.37	Sales Q/Q	6.74%	SMA50	0.26%	Rel Volume	0.18	Prev Close	166.31
Employees	2800	LT Debt/Eq	1.11	Earnings	Feb 24 AMC	SMA200	23.79%	Avg Volume	1.17M	Price	167.79
IPO	Jun 01, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.72% 1.35%	Trades		Volume	164,208	Change	0.89%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Downgrade	UBS	Buy → Neutral	$188
Jul-15-25	Initiated	Deutsche Bank	Buy	$152
Mar-07-25	Upgrade	UBS	Neutral → Buy	$145 → $179
Feb-26-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-13-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$130 → $170
Dec-12-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$140 → $175
Jun-05-24	Initiated	Goldman	Buy	$169
Jan-03-24	Initiated	Robert W. Baird	Outperform	$160
Nov-27-23	Downgrade	UBS	Buy → Neutral	$170 → $135
Sep-29-23	Initiated	Raymond James	Mkt Perform
Jun-12-23	Resumed	Wells Fargo	Equal Weight	$184 → $140
Dec-09-22	Upgrade	Goldman	Neutral → Buy	$192 → $190
Jun-14-22	Initiated	UBS	Buy	$194
Apr-06-22	Downgrade	Goldman	Buy → Neutral	$202 → $196
Nov-19-21	Resumed	Goldman	Buy	$198
Oct-07-21	Resumed	Jefferies	Buy	$172
Oct-05-21	Initiated	Citigroup	Buy	$200
Sep-23-21	Initiated	Needham	Buy	$220
May-19-21	Resumed	JP Morgan	Overweight	$183 → $206
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$186

Show Previous Ratings

Today 10:00AM	Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Feb-11-26 08:36AM	Is the Options Market Predicting a Spike in Jazz Pharmaceuticals Stock? (Zacks)
Feb-10-26 04:15PM	Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 (PR Newswire)
Feb-09-26 07:51AM	Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
Feb-03-26 07:56AM	New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings (Zacks)
06:55AM	Loading…
06:55AM	Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial (Insider Monkey)
Jan-30-26 12:39PM	This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth (Investor's Business Daily)
Jan-27-26 12:22PM	Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? (Motley Fool)
Jan-26-26 10:15AM	Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? (Zacks)
Jan-16-26 06:24AM	Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading (BioPharma Dive)
Jan-15-26 12:41PM	JPM26: Jazz sells PRV for $200m, targets deals in 2026 (Pharmaceutical Technology)
Jan-13-26 07:43AM	Jazz Pharmaceuticals price target raised to $235 from $210 at Needham (TipRanks)
Jan-09-26 12:19PM	Jazz Pharmaceuticals touts Phase 3 zanidatamab OS win in HER2+ GEA, eyes FDA sBLA in H1 (MarketBeat)
Jan-08-26 07:50PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) -5.38%
04:05PM	Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer (PR Newswire)
01:32PM	Loading…
Jan-06-26 01:32PM	Ziihera (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA Including More Than Two Years Median Overall Survival Benefit (PR Newswire)
Dec-28-25 10:37PM	Reflecting On Pharmaceuticals Stocks' Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) (StockStory)
Dec-17-25 11:03PM	3 Reasons JAZZ is Risky and 1 Stock to Buy Instead (StockStory)
04:15PM	Jazz Pharmaceuticals to Participate in Upcoming Investor Events (PR Newswire)
Dec-05-25 11:30AM	Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue? (Zacks)
09:00AM	Jazz Pharmaceuticals to Present Extensive New Data and Real-World Evidence Highlighting Epidiolex (cannabidiol) Outcomes in Treatment-Resistant Epilepsies at the American Epilepsy Society 2025 Annual Meeting (PR Newswire)
07:12AM	Trials, Sales Wins Sends Jazz Pharmaceuticals Higher (FX Empire)
Dec-02-25 04:05PM	Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Nov-26-25 09:13AM	Why Jazz Pharmaceuticals May Be a Stealth Cannabis Winner (Zacks)
Nov-24-25 09:41AM	Booking, Carvana upgraded: Wall Street's top analyst calls (The Fly)
09:20AM	Here are Mondays Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More (24/7 Wall St.)
Nov-20-25 01:37AM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
Nov-18-25 04:15PM	Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference (PR Newswire) +6.13%
12:16PM	JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data (Zacks)
03:38AM	Zymeworks to change course, pursue royalty-driven biotech model (BioPharma Dive)
12:43AM	Loading…
12:43AM	Jazz Pharma (JAZZ) Hits Fresh 52-Week High on Strong Cancer Treatment Trial (Insider Monkey)
Nov-17-25 07:29PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) +20.57%
04:44PM	Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer (Investor's Business Daily)
04:13PM	Stocks to Watch Recap: Alphabet, Tesla, Netflix, Zymeworks (The Wall Street Journal)
11:41AM	Why Is Jazz Pharmaceuticals (JAZZ) Stock Soaring Today (StockStory)
09:35AM	Stocks to Watch Monday: Alphabet, Tesla, Netflix, Zymeworks (The Wall Street Journal)
09:15AM	Why Jazz (JAZZ) International Revenue Trends Deserve Your Attention (Zacks)
08:10AM	Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar. (Barrons.com)
06:00AM	Positive HERIZON-GEA-01 Phase 3 Results Support Ziihera (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and Ziihera Combination Regimens as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (PR Newswire)
Nov-12-25 12:36AM	The Top 5 Analyst Questions From Jazz Pharmaceuticals's Q3 Earnings Call (StockStory)
Nov-11-25 07:45AM	Jazz Pharmaceuticals Showcases New Clinical and Translational Data for Modeyso (dordaviprone) in H3 K27M-mutant Diffuse Midline Glioma at SNO 2025 (PR Newswire)
Nov-06-25 10:50AM	JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View (Zacks)
12:33AM	JAZZ Q3 Deep Dive: New Drug Launches and Portfolio Expansion Drive Strong Results (StockStory)
12:01AM	Jazz Pharmaceuticals PLC (JAZZ) Q3 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Nov-05-25 07:00PM	Jazz (JAZZ) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Beat Estimates (Zacks)
04:32PM	Jazz: Q3 Earnings Snapshot (Associated Press Finance)
04:25PM	Jazz Pharmaceuticals's (NASDAQ:JAZZ) Q3: Beats On Revenue (StockStory)
04:05PM	Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance (PR Newswire)
Nov-04-25 10:28AM	AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
Nov-03-25 10:17PM	Earnings To Watch: Jazz Pharmaceuticals (JAZZ) Reports Q3 Results Tomorrow (StockStory)
Oct-29-25 10:00AM	Earnings Preview: Jazz Pharmaceuticals (JAZZ) Q3 Earnings Expected to Decline (Zacks)
Oct-28-25 04:05PM	Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors (PR Newswire)
Oct-24-25 12:02AM	3 Reasons to Sell JAZZ and 1 Stock to Buy Instead (StockStory)
Oct-22-25 04:15PM	Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 5, 2025 (PR Newswire)
Oct-21-25 06:55AM	Iambic partners with Jazz; Merck breaks ground on $3B plant (BioPharma Dive)
Oct-16-25 02:14PM	Praxis Precision's tremor-drug trial has succeeded where others have failed. The stock is skyrocketing. (MarketWatch)
Oct-06-25 01:13PM	Roche Wins FDA Nod for Label Expansion of Tecentriq in Lung Cancer (Zacks)
Oct-02-25 06:37PM	FDA Approves Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (PR Newswire)
01:53AM	Jazz Pharmaceuticals (JAZZ) Gets Price Target Boost Following Positive Xywav Phase 4 Data (Insider Monkey)
Oct-01-25 11:10AM	Headlines Boost Pharma Stocks. Charts of Pfizer, Johnson & Johnson, Jazz Pharmaceuticals Speak to Rally Into Year End (Barrons.com)
Sep-30-25 09:45AM	Can Auvelity Drive Axsome's Growth Through the Rest of 2025? (Zacks)
Sep-27-25 12:59AM	Piper Sandler Reaffirms Jazz Pharmaceuticals (JAZZ) Price Target Ahead of Trial Data (Insider Monkey)
Sep-24-25 08:45AM	Here's Why JAZZ Stock Is an Unconventional Cannabis Investment (Zacks)
Sep-23-25 07:11PM	Jazz Pharmaceuticals plc (JAZZ) Advances Rare Cancer Portfolio with First CNS Glioma Therapy Approval (Insider Monkey)
Sep-22-25 07:45AM	Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses (PR Newswire)
Sep-16-25 09:30AM	Jazz Pharmaceuticals plc (JAZZ) Wins FDA Nod for Modeyso in Rare Pediatric Brain Tumors (Insider Monkey)
Sep-09-25 07:45AM	Modeyso (dordaviprone) Included in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for H3 K27M-mutant Diffuse Glioma (PR Newswire)
Sep-02-25 01:34AM	Jazz Pharmaceuticals (JAZZ) Price Target Raised After Modeyso Commercial Strategy Update (Insider Monkey)
Aug-29-25 12:27PM	Axsome Shares Up 20% in a Month: How Should You Play the Stock? (Zacks)
05:04AM	Jazz Pharmaceuticals plc (JAZZ) Wins FDA Accelerated Approval for Modeyso Brain Cancer Therapy (Insider Monkey)
Aug-28-25 11:49PM	Jazz Pharmaceuticals (JAZZ) Sings License with Saniona for SAN2355 (Insider Monkey)
Aug-22-25 11:57PM	BofA Raises PT on Jazz Pharmaceuticals (JAZZ) to $225 From $217 (Insider Monkey)
06:27AM	FDA cancels adcomm on Biohaven drug; Catalent lays off staff (BioPharma Dive)
Aug-21-25 04:15PM	Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare Conference (PR Newswire)
09:49AM	JAZZ Inks $1B Licensing Deal With Saniona for Epilepsy Drug (Zacks)
Aug-20-25 04:15PM	Jazz Pharmaceuticals to Host Modeyso (dordaviprone) Investor Webcast on August 27, 2025 (PR Newswire)
07:30AM	Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355 (PR Newswire)
Aug-19-25 07:17PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
Aug-17-25 11:35PM	Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks (StockStory)
Aug-14-25 04:03AM	United States Narcolepsy Drugs Market to Reach US$ 2,233.56 Million by 2033 - 7.88% CAGR Driven by Novel Therapies and Better Diagnosis (GlobeNewswire)
Aug-13-25 04:30PM	Onco360 adds Modeyso (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider (GlobeNewswire)
12:16AM	The 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals's Q2 Earnings Call (StockStory)
Aug-12-25 11:48PM	JAZZ Q2 Deep Dive: Pipeline Milestones and Oncology Headwinds Shape Outlook (StockStory)
Aug-08-25 09:15AM	Don't Overlook Jazz (JAZZ) International Revenue Trends While Assessing the Stock (Zacks)
05:07AM	Elevidys sales weaken; Neumora gets into obesity (BioPharma Dive)
Aug-07-25 03:35PM	Why Jazz Pharmaceuticals (JAZZ) Stock Is Trading Up Today (StockStory) +5.81%
05:00AM	FDA gives accelerated approval to Jazz Pharmas diffuse midline glioma therapy (Pharmaceutical Technology)
Aug-06-25 07:08PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) -6.42%
03:07PM	Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma (PR Newswire)
09:22AM	JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut (Zacks)
03:29AM	Jazz Pharmaceuticals PLC (JAZZ) Q2 2025 Earnings Call Highlights: Strong Neuroscience ... (GuruFocus.com)
Aug-05-25 06:30PM	Jazz (JAZZ) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
06:13PM	Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Q2 In Line With Expectations But Stock Drops (StockStory)
05:15PM	Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:13PM	Jazz: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance (PR Newswire)
11:36AM	AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
Aug-03-25 11:01PM	Jazz Pharmaceuticals (JAZZ) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
Jul-30-25 11:44AM	Morgan Stanley Reduces PT on Jazz Pharmaceuticals plc (JAZZ) from $166 to $165; Maintains 'Buy' Rating (Insider Monkey)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Henderson Mary Elizabeth	SVP, Technical Operations	Dec 09 '25	Sale	169.51	2,238	379,366	19,508	Dec 11 05:19 PM
MARY ELIZABETH HENDERSON	Officer	Dec 09 '25	Proposed Sale	169.51	2,238	379,365		Dec 09 06:52 PM
Carr Patricia	SVP, Chief Accounting Officer	Dec 05 '25	Option Exercise	140.67	4,500	633,015	11,512	Dec 09 05:25 PM
Carr Patricia	SVP, Chief Accounting Officer	Dec 05 '25	Sale	171.20	4,660	797,783	7,012	Dec 09 05:25 PM
PATRICIA CARR	Officer	Dec 05 '25	Proposed Sale	171.20	4,660	797,783		Dec 05 04:03 PM
O'Keefe Kenneth W	Director	Dec 02 '25	Proposed Sale	176.59	1,249	220,561		Dec 01 08:55 PM
COZADD BRUCE C	Director	Nov 26 '25	Option Exercise	123.36	77,500	9,560,400	470,832	Dec 01 06:14 PM
COZADD BRUCE C	Director	Nov 26 '25	Sale	177.81	77,500	13,780,337	393,332	Dec 01 06:14 PM
BRUCE COZADD	Director	Nov 26 '25	Proposed Sale	177.81	77,500	13,780,337		Nov 26 05:37 PM
McSharry Heather Ann	Director	Nov 20 '25	Option Exercise	138.08	3,415	471,543	23,864	Nov 24 05:47 PM
McSharry Heather Ann	Director	Nov 20 '25	Sale	177.78	3,415	607,127	20,449	Nov 24 05:47 PM
COZADD BRUCE C	Director	Nov 18 '25	Sale	181.09	18,000	3,259,538	390,826	Nov 20 08:03 PM
Carr Patricia	SVP, Chief Accounting Officer	Nov 18 '25	Option Exercise	136.18	5,250	714,945	12,262	Nov 20 06:13 PM
Carr Patricia	SVP, Chief Accounting Officer	Nov 18 '25	Sale	182.06	5,319	968,402	7,012	Nov 20 06:13 PM
Winningham Rick E	Director	Nov 18 '25	Sale	180.86	5,500	994,728	8,893	Nov 20 05:54 PM
HEATHER MCSHARRY	Director	Nov 20 '25	Proposed Sale	177.78	3,415	607,127		Nov 20 04:05 PM
Henderson Mary Elizabeth	Officer	Nov 19 '25	Proposed Sale	127.23	2,961	376,740		Nov 19 08:59 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Nov 17 '25	Sale	168.26	7,159	1,204,573	72,628	Nov 19 08:31 PM
Bruce C Cozadd	Officer	Nov 18 '25	Proposed Sale	181.09	18,000	3,259,537		Nov 18 07:08 PM
RICK WINNINGHAM	Director	Nov 18 '25	Proposed Sale	180.86	5,500	994,728		Nov 18 05:20 PM
PATRICIA CARR	Officer	Nov 18 '25	Proposed Sale	182.06	5,319	968,402		Nov 18 04:59 PM
ROBERT IANNONE	Officer	Nov 17 '25	Proposed Sale	168.26	7,159	1,204,573		Nov 17 04:06 PM
COZADD BRUCE C	Director	Oct 03 '25	Sale	140.00	3,500	490,000	408,826	Oct 03 09:27 PM
COZADD BRUCE C	Director	Oct 01 '25	Sale	131.78	2,000	263,560	412,326	Oct 03 09:27 PM
Bruce C Cozadd	Officer	Oct 03 '25	Proposed Sale	140.00	3,500	490,000		Oct 03 04:10 PM
COZADD BRUCE C	Director	Sep 02 '25	Sale	128.62	6,000	771,690	429,973	Sep 04 05:48 PM
Winningham Rick E	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 03:02 PM
Kennedy Patrick	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:56 PM
ENRIGHT PATRICK G	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:46 PM
RIEDEL NORBERT G	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:40 PM
Smith Mark Douglas	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:33 PM
Hamill Laura	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:26 PM
O'Keefe Kenneth W	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:20 PM
Cook Jennifer E.	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:13 PM
McSharry Heather Ann	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:06 PM
ORiordan Anne	Director	Aug 08 '25	Proposed Sale	112.00	3,731	417,872		Aug 08 02:00 PM
COZADD BRUCE C	Chairman & CEO	Aug 01 '25	Sale	113.21	1,000	113,210	435,973	Aug 05 04:54 PM
COZADD BRUCE C	Officer	Aug 01 '25	Proposed Sale	121.80	9,000	1,096,210		Aug 01 03:28 PM
COZADD BRUCE C	Chairman & CEO	Jul 01 '25	Sale	107.63	1,000	107,630	436,973	Jul 03 02:56 PM
COZADD BRUCE C	Officer	Jul 01 '25	Proposed Sale	107.63	1,000	107,630		Jul 01 04:15 PM
COZADD BRUCE C	Chairman & CEO	Jun 03 '25	Sale	110.00	500	55,000	437,973	Jun 04 04:50 PM
COZADD BRUCE C	Chairman & CEO	Jun 02 '25	Sale	107.90	500	53,950	438,473	Jun 04 04:50 PM
COZADD BRUCE C	Officer	Jun 02 '25	Proposed Sale	108.95	1,000	108,950		Jun 02 05:03 PM
Mulligan Seamus	Director	May 09 '25	Buy	98.26	100,000	9,826,120	100,000	May 13 06:51 PM
Mulligan Seamus	Director	May 12 '25	Buy	103.00	1,621	166,962	101,621	May 13 06:51 PM
COZADD BRUCE C	Chairman & CEO	May 01 '25	Sale	116.35	1,000	116,350	439,307	May 05 07:00 PM
COZADD BRUCE C	Chairman & CEO	May 02 '25	Sale	120.00	500	60,000	438,807	May 05 07:00 PM
COZADD BRUCE C	Officer	May 01 '25	Proposed Sale	117.57	1,500	176,350		May 01 04:09 PM
COZADD BRUCE C	Chairman & CEO	Apr 01 '25	Sale	123.75	1,500	185,625	440,307	Apr 03 05:32 PM
COZADD BRUCE C	Officer	Apr 01 '25	Proposed Sale	125.31	2,000	250,625		Apr 01 04:32 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Mar 10 '25	Sale	138.41	2,403	332,605	79,621	Mar 12 02:24 PM
Carr Patricia	SVP, Chief Accounting Officer	Mar 10 '25	Sale	137.81	1,140	157,103	7,012	Mar 11 06:17 PM
Iannone Robert	Officer	Mar 10 '25	Proposed Sale	145.00	1,767	256,215		Mar 10 06:01 PM
Carr Patricia	Officer	Mar 10 '25	Proposed Sale	137.81	1,140	157,103		Mar 10 05:36 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Mar 07 '25	Sale	138.60	7,080	981,298	82,024	Mar 07 06:49 PM
ROBERT IANNONE	Officer	Mar 07 '25	Proposed Sale	138.73	5,466	758,305		Mar 07 05:14 PM
Iannone Robert	Officer	Mar 07 '25	Proposed Sale	142.26	4,017	571,476		Mar 07 05:04 PM
Henderson Mary Elizabeth	Officer	Mar 07 '25	Proposed Sale	139.00	1,295	180,005		Mar 07 03:15 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '25	Option Exercise	113.77	4,813	547,562	12,737	Mar 03 07:21 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '25	Sale	144.42	4,813	695,075	8,237	Mar 03 07:21 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 28 '25	Sale	143.29	773	110,767	9,485	Mar 03 07:21 PM
Patil Neena M	EVP & Chief Legal Officer	Feb 27 '25	Sale	144.87	3,800	550,506	33,318	Mar 03 07:18 PM
COZADD BRUCE C	Chairman & CEO	Mar 03 '25	Sale	144.25	6,500	937,625	464,058	Mar 03 07:13 PM
COZADD BRUCE C	Officer	Mar 03 '25	Proposed Sale	144.25	6,500	937,625		Mar 03 04:44 PM
Carr Patricia	Officer	Feb 28 '25	Proposed Sale	143.30	773	110,767		Feb 28 05:43 PM
Carr Patricia	Officer	Feb 27 '25	Proposed Sale	139.00	1,641	228,099		Feb 27 08:05 PM
Carr Patricia	Officer	Feb 27 '25	Proposed Sale	144.42	4,813	695,075		Feb 27 05:04 PM
Patil Neena M	Officer	Feb 27 '25	Proposed Sale	144.87	3,800	550,518		Feb 27 04:56 PM

Open in Screener

VERA

Vera Therapeutics Inc

Feb 17 • 02:24PM ET

43.12

+0.90 2.13 %

Healthcare • Biotechnology • USA • NASD

VERA Vera Therapeutics Inc daily Stock Chart

Peers: ARVN INCY ITCI ALXO BCRX RIGL LGND KURA CRVS AVIR

| Held by: VTI XBI IWM VXF IWO IBB SCHA VTWO VHT FESM

Index	RUT	P/E	-	EPS (ttm)	-3.99	Insider Own	19.17%	Shs Outstand	63.89M	Perf Week	-1.66%
Market Cap	3.02B	Forward P/E	-	EPS next Y	-4.59	Insider Trans	-0.32%	Shs Float	56.63M	Perf Month	-6.83%
Enterprise Value	2.60B	PEG	-	EPS next Q	-1.28	Inst Own	90.72%	Short Float	14.29%	Perf Quarter	51.99%
Income	-251.94M	P/S	-	EPS this Y	-65.38%	Inst Trans	2.29%	Short Ratio	5.94	Perf Half Y	100.19%
Sales	0.00M	P/B	6.91	EPS next Y	-1.00%	ROA	-56.87%	Short Interest	8.09M	Perf YTD	-14.85%
Book/sh	6.24	P/C	6.07	EPS next 5Y	2.47%	ROE	-73.25%	52W High	56.05 -23.07%	Perf Year	57.03%
Cash/sh	7.10	P/FCF	-	EPS past 3/5Y	-21.52% 4.49%	ROIC	-52.97%	52W Low	18.53 132.70%	Perf 3Y	414.56%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.75% 5.23%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-53.44%	Oper. Margin	-	ATR (14)	2.32	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	12.09	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	45.27	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	12.09	EPS Q/Q	-48.06%	SMA20	-3.07%	Beta	1.17	Target Price	75.15
Payout	-	Debt/Eq	0.19	Sales Q/Q	-	SMA50	-8.14%	Rel Volume	0.41	Prev Close	42.22
Employees	112	LT Debt/Eq	0.19	Earnings	Nov 05 BMO	SMA200	41.41%	Avg Volume	1.36M	Price	43.12
IPO	May 14, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.40% -	Trades		Volume	425,266	Change	2.13%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-25	Initiated	BofA Securities	Buy	$48
Aug-04-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-05-25	Resumed	H.C. Wainwright	Buy	$75
Feb-04-25	Initiated	Wolfe Research	Outperform	$49
Jan-28-25	Initiated	Goldman	Buy	$58
Nov-21-24	Initiated	Wells Fargo	Overweight	$70
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Jan-25-24	Initiated	Oppenheimer	Outperform	$26
Jan-08-24	Initiated	Cantor Fitzgerald	Overweight
Dec-18-23	Initiated	Raymond James	Outperform	$29
Nov-10-23	Upgrade	Jefferies	Hold → Buy	$18 → $26
Aug-16-23	Initiated	Guggenheim	Buy	$27
Jan-04-23	Downgrade	Wedbush	Outperform → Neutral	$33 → $8
Jan-04-23	Downgrade	Jefferies	Buy → Hold	$32 → $6
Jul-12-22	Initiated	JP Morgan	Overweight	$35
May-02-22	Initiated	H.C. Wainwright	Buy	$35
Apr-19-22	Initiated	Wedbush	Outperform	$32

Show Previous Ratings

Feb-16-26 12:23PM	Atacicept's Potential Approval Drives Favorable Views on Vera Therapeutics (VERA) (Insider Monkey)
Feb-07-26 11:35AM	Vera Therapeutics, Inc. (VERA): A Bull Case Theory (Insider Monkey)
Feb-06-26 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.23%
Jan-30-26 12:24AM	Is Vera Therapeutics (VERA) One of the Best High Short Interest Stocks with Biggest Upside Potential? (Insider Monkey)
Jan-28-26 07:30AM	Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer (GlobeNewswire)
11:09AM	Loading…
Jan-23-26 11:09AM	Clinical Success Lifts Vera (VERA) Shares, Boosting Fund Returns (Insider Monkey)
Jan-15-26 11:35AM	Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept (Insider Monkey)
Jan-14-26 09:55AM	Wall Street Analysts See a 53.05% Upside in Vera Therapeutics (VERA): Can the Stock Really Move This High? (Zacks)
Jan-09-26 01:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-08-26 07:30AM	Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-26 07:41PM	Why Vera Therapeutics Stock Zoomed Higher Today (Motley Fool)
07:30AM	Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy (GlobeNewswire)
Dec-09-25 08:57PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire)
Dec-08-25 04:01PM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
Dec-05-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.37%
07:42PM	Loading…
Dec-02-25 07:42PM	Why Vera Therapeutics Stock Rocked the Market on Tuesday (Motley Fool) +12.88% +10.77%
01:09PM	Stock Market Today: MongoDB, Boeing, and Intel Define Tuesday Trade As Market Bounces Back From Post-Thanksgiving Blues (TheStreet)
Nov-26-25 07:45PM	Why Vera Therapeutics Stock Crushed it Today (Motley Fool) +13.25%
04:05PM	Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors (GlobeNewswire)
Nov-24-25 07:25AM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-18-25 02:20PM	Vera Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-16-25 10:14PM	H.C. Wainwright Maintains Its Bullish Stance on Vera Therapeutics (VERA), Sees Strong Future Revenue Growth (Insider Monkey)
Nov-14-25 09:01AM	Yale University's Strategic Investment in Vera Therapeutics Inc: A 32.26% Portfolio Stake (GuruFocus.com)
Nov-10-25 07:29AM	Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit (GlobeNewswire) +14.72%
Nov-07-25 06:27PM	Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy (GlobeNewswire)
04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 09:51AM	Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine (GlobeNewswire)
Nov-05-25 07:29AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-22-25 08:00AM	Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET (GlobeNewswire)
Oct-20-25 11:08PM	BofA Initiates Coverage of Vera Therapeutics (VERA) With a Buy Rating (Insider Monkey)
09:12AM	Loading…
Oct-17-25 09:12AM	Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025 (GlobeNewswire)
Oct-10-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +10.46%
Aug-26-25 04:05PM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire) +5.62%
Aug-08-25 04:05PM	Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-25 07:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 09:35AM	Coinbase downgraded, Spotify upgraded: Wall Street's top analyst calls (The Fly)
Jul-10-25 07:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-02-25 08:07AM	Millions in Insider Buying Point to These 2 Stocks Heres What It Could Signal (TipRanks)
Jun-12-25 01:57PM	Analysts Can't Get Enough of These Little-Known Biopharma Stocks (MarketBeat)
Jun-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-06-25 11:02AM	Biotech Stock Vera Is Slumping After Monster Gain (Barrons.com) -25.89%
07:49AM	Vera Therapeutics stock sinks following competitors successful trial (Investing.com)
Jun-04-25 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
Jun-03-25 06:30AM	Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans (GlobeNewswire)
02:22AM	Why Vera Therapeutics, Inc. (VERA) Skyrocketed On Monday (Insider Monkey)
Jun-02-25 06:30AM	Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy (GlobeNewswire) +67.49%
04:51AM	Vera drug scores in closely watched study in rare kidney disease (BioPharma Dive)
May-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-25 08:00AM	Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) -13.79%
Apr-09-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.76%
02:51PM	Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch (Benzinga)
Apr-03-25 08:00AM	Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN (GlobeNewswire)
Mar-11-25 04:28PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-27-25 08:00AM	Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) +5.91%
Feb-26-25 08:25AM	Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-13-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -19.66%
Jan-14-25 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 07:00AM	Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor (GlobeNewswire) -6.08%
Jan-07-25 04:05PM	Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 06:29PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-22-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-18-24 08:00AM	Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer (GlobeNewswire)
Nov-11-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:55AM	Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet (Zacks)
08:00AM	Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study (GlobeNewswire)
Nov-08-24 04:05PM	Vera Therapeutics to Participate at Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-29-24 08:21PM	Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock (GlobeNewswire) -9.23% -5.42%
09:25AM	Vera Therapeutics price target raised to $64 from $56 at Guggenheim (TipRanks)
Oct-28-24 05:43PM	Vera Therapeutics Breaks Out On Promising Results For Kidney Drug (Investor's Business Daily) +15.21%
05:37PM	Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock (GlobeNewswire)
10:33AM	Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years (Benzinga)
10:13AM	Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug (Investor's Business Daily)
Oct-26-24 07:30PM	Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
Oct-04-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-02-24 06:30AM	Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire)
06:30AM	Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases (GlobeNewswire)
Sep-26-24 03:31PM	Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024? (Insider Monkey)
Sep-16-24 08:00AM	Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024 (GlobeNewswire) +6.90%
Sep-12-24 08:00AM	Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN (GlobeNewswire) -5.08%
Sep-10-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-05-24 01:07AM	Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-03-24 08:27AM	Adobe Stock Added to JP Morgan Focus List. Heres Why. (Barrons.com)
08:27AM	Adobe and 2 More Stocks Added to JP Morgan Focus List. Heres Why. (Barrons.com)
07:49AM	Load Up on Adobe and These 2 Stocks This September, J.P. Morgan Says (Barrons.com)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-29-24 08:00AM	Vera Therapeutics to Participate at September Investor Conferences (GlobeNewswire)
Aug-09-24 04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-08-24 08:00AM	Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-05-24 04:30PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-01-24 08:00AM	Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer (GlobeNewswire)
Jun-11-24 04:01PM	Vera Therapeutics Appoints Christy J. Oliger to Board of Directors (GlobeNewswire)
Jun-07-24 04:05PM	Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
04:05PM	Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-28-24 08:00AM	Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN) (GlobeNewswire)
May-25-24 09:40AM	Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress (GlobeNewswire)
May-17-24 04:27PM	Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing (MT Newswires)
May-10-24 05:38AM	Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating (MT Newswires)
May-09-24 01:53PM	VERA Stock Earnings: Vera Therapeutics Misses EPS for Q1 2024 (InvestorPlace) -5.81%

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 17 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 15 '25	Sale	50.08	10,000	500,767	22,500	Dec 17 04:05 PM
ENRIGHT PATRICK G	Director	Dec 11 '25	Buy	42.50	5,882	249,985	5,882	Dec 15 08:07 PM
WILLIAM TURNER	Officer	Dec 15 '25	Proposed Sale	49.80	10,000	498,000		Dec 15 04:17 PM
Turner William D.	Chief Regulatory Officer	Dec 08 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 10 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 08 '25	Sale	45.31	10,000	453,053	22,500	Dec 10 04:05 PM
WILLIAM TURNER	Officer	Dec 08 '25	Proposed Sale	44.90	10,000	449,000		Dec 08 04:41 PM
Turner William D.	Chief Regulatory Officer	Dec 03 '25	Option Exercise	15.53	10,000	155,300	32,500	Dec 04 04:05 PM
Turner William D.	Chief Regulatory Officer	Dec 03 '25	Sale	40.00	10,000	400,000	22,500	Dec 04 04:05 PM
WILLIAM TURNER	Officer	Dec 03 '25	Proposed Sale	37.25	10,000	372,500		Dec 03 04:31 PM
Carter Jason S	Chief Legal Officer	Nov 21 '25	Sale	27.82	3,864	107,498	49,136	Nov 25 04:05 PM
Carter Jason S	Officer	Nov 21 '25	Proposed Sale	27.87	3,864	107,690		Nov 24 09:22 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Nov 13 '25	Option Exercise	3.94	10,000	39,396	57,839	Nov 13 08:57 PM
Young Joseph R	SVP, FINANCE, CHIEF ACCT OFFCR	Nov 11 '25	Sale	29.06	15,000	435,874	47,839	Nov 13 08:57 PM
ENRIGHT PATRICK G	Director	Jun 23 '25	Buy	20.87	209,393	4,369,676	3,569,522	Jun 25 08:07 PM
ENRIGHT PATRICK G	Director	Jun 24 '25	Buy	22.35	40,607	907,635	3,596,593	Jun 25 08:07 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 21 '25	Sale	27.89	10,613	296,032	213,740	Feb 27 04:05 PM
Fordyce Marshall	PRESIDENT AND CEO	Feb 26 '25	Sale	27.65	9,075	250,882	204,665	Feb 27 04:05 PM
MARSHALL FORDYCE	Director	Feb 26 '25	Proposed Sale	27.10	9,075	245,932		Feb 26 04:21 PM

BIOA

BioAge Labs Inc

ZBIO

Zenas Biopharma Inc

JAZZ

Jazz Pharmaceuticals plc

VERA

Vera Therapeutics Inc

Upgrade your FINVIZ experience